Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-CD3 monoclonal antibody is now in a pivotal Phase II/III clinical trial for treating underlying disease in type 1 diabetes, Lilly tells “The Pink Sheet” DAILY.

You may also be interested in...



Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.

Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.

Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

GlaxoSmithKline and Tolerx announced March 11 that their humanized anti-CD3 monoclonal antibody, otelixizumab failed to meet the primary endpoint in the Phase III DEFEND-1 trial for type 1 diabetes, and they were halting recruitment and dosing in another Phase III trial, DEFEND-2, while they review the DEFEND-1 results.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel